Atropine is a small molecule commercialized by Ocumension Therapeutics, with a leading Phase III program in Myopia. According to Globaldata, it is involved in 1 clinical trial, which is ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of Atropine’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

The revenue for Atropine is expected to reach an annual total of $9 mn by 2033 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Atropine Overview

Atropine is under development for the treatment of myopia (nearsightedness) in children and adolescents. It is administered ophthalmic route. It acts by targeting muscarinic cholinergic receptor.

Ocumension Therapeutics Overview

Ocumension Therapeutics (Ocumension) develops and provides prescription medicines that meet the evolving needs of patients, healthcare professionals, and caregivers. Ocumension is headquartered in Suzhou, Suzhou, China.

The company reported revenues of (Renminbi) CNY56.2 million for the fiscal year ended December 2021 (FY2021), compared to a revenue of CNY13.1 million in FY2020. The operating loss of the company was CNY246.1 million in FY2021, compared to an operating loss of CNY2,264.8 million in FY2020. The net loss of the company was CNY260 million in FY2021, compared to a net loss of CNY2,264.9 million in FY2020.

For a complete picture of Atropine’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.